Ekso Bionics (NASDAQ:EKSO) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Ekso Bionics (NASDAQ:EKSO) in a report published on Sunday. The firm issued a hold rating on the stock.

A number of other equities analysts also recently issued reports on EKSO. HC Wainwright lowered their price objective on Ekso Bionics from $10.00 to $9.00 and set a “buy” rating for the company in a research report on Tuesday, October 29th. Lake Street Capital lowered their price target on shares of Ekso Bionics from $2.50 to $2.00 and set a “buy” rating for the company in a report on Tuesday, October 29th.

Ekso Bionics Trading Up 2.2 %

Shares of EKSO stock opened at $0.89 on Friday. Ekso Bionics has a twelve month low of $0.83 and a twelve month high of $3.13. The stock’s fifty day simple moving average is $1.10 and its 200 day simple moving average is $1.14. The company has a quick ratio of 2.14, a current ratio of 2.81 and a debt-to-equity ratio of 0.28. The firm has a market capitalization of $19.58 million, a P/E ratio of -1.34 and a beta of 1.47.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Monday, October 28th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.02). The business had revenue of $4.13 million for the quarter, compared to the consensus estimate of $6.00 million. Ekso Bionics had a negative net margin of 62.95% and a negative return on equity of 83.09%. During the same period in the previous year, the business posted ($0.24) EPS. As a group, sell-side analysts predict that Ekso Bionics will post -0.48 EPS for the current fiscal year.

Institutional Trading of Ekso Bionics

A hedge fund recently raised its stake in Ekso Bionics stock. Kent Lake Capital LLC lifted its holdings in shares of Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) by 322.3% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 596,050 shares of the company’s stock after purchasing an additional 454,892 shares during the period. Kent Lake Capital LLC owned 3.28% of Ekso Bionics worth $811,000 at the end of the most recent reporting period. 6.42% of the stock is owned by institutional investors and hedge funds.

About Ekso Bionics

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.